Asunto(s)
Ácido Micofenólico/análogos & derivados , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Antiinflamatorios no Esteroideos/uso terapéutico , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/metabolismo , Humanos , Ácido Micofenólico/química , Ácido Micofenólico/farmacocinética , Ácido Micofenólico/uso terapéutico , Profármacos/química , Profármacos/farmacocinética , Profármacos/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/metabolismoRESUMEN
Pemphigus vulgaris (PV) is a life threatening autoimmune blistering disease of skin and mucous membranes. Advent of systemic steroids has greatly reduced the mortality rate. However, steroids and adjuvant immunosuppressive therapy are nowadays frequent contributory agents of morbidity and mortality of PV. Mycophenolate mofetil (MMF) has been reported to be an effective adjuvant to systemic steroids. It helps in increasing the immunosuppressive effect and minimizing the toxicities by steroid sparing effect. However, its efficacy in refractory cases of PV is not well documented. The lowest possible dose with satisfactory therapeutic efficacy and least side effects is known. We used MMF 1 g/day and systemic steroids in 3 Indian patients with pemphigus vulgaris who were resistant to systemic steroid monotherapy or combination treatment with azathioprine. In our experience, MMF offers an effective adjuvant with minimal side-effects in the treatment of resistant PV.